Newsroom Stay up to date with what’s happening at ONO PHARMA USA. Breadcrumb Newsroom Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune DiseasesLicensingAugust 31, 2023 Ono Pharmaceutical Co., Ltd. Announced 2023 1Q Financial ResultsCompanyJuly 31, 2023 Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial ResultsCompanyMay 10, 2023 ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabsCompanyApril 18, 2023 ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System LymphomaR & DMarch 22, 2023 Ono Pharmaceutical Co., Ltd. Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific ProteinLicensingFebruary 24, 2023 Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and SyriaCompanyFebruary 17, 2023 Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial ResultsCompanyJanuary 31, 2023 Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ TherapeuticsLicensingJanuary 25, 2023 Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022SustainabilityDecember 27, 2022 Pagination First page « First Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page Last »